Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Public ClinicalTrials.gov record NCT07752979. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Dose-Finding Study to Assess the Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight with weight-related comorbidities. ABBV-295 is an investigational long-acting amylin analog being developed for chronic weight management. Participants are placed into multiple treatment groups with different dosing paradigms of ABBV-295 or placebo. Participants will not know which treatment they are receiving, and there is a chance of being assigned to placebo. Adults with obesity or overweight (as defined by BMI) with weight-related comorbidities will be enrolled. Approximately 360 participants will be enrolled in the study at approximately 70 sites in the United States and Puerto Rico. Participants will receive subcutaneous (SC) injections of ABBV-295 solution for injection or matching placebo administered via pre-filled syringes for 52 weeks during the Double-Blind Period. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study identification
- NCT ID
- NCT07752979
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 360 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2026
- Primary completion
- Feb 29, 2028
- Completion
- Feb 29, 2028
- Last update posted
- Aug 30, 2026
2026 – 2028
United States locations
- U.S. sites
- 33
- U.S. states
- 12
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Headlands Research - Scottsdale /ID# 282571 | Scottsdale | Arizona | 85260 | Recruiting |
| Southern California Dermatology /ID# 282011 | Santa Ana | California | 92701 | Recruiting |
| Encompass Clinical Research /ID# 282483 | Spring Valley | California | 91978 | Recruiting |
| Diablo Clinical Research /ID# 282530 | Walnut Creek | California | 94598 | Recruiting |
| Innovative Research of West Florida /ID# 281963 | Clearwater | Florida | 33756 | Recruiting |
| Altus Clinical Research - Lake Worth - South Congress Avenue /ID# 281979 | Lake Worth | Florida | 33461 | Recruiting |
| South Broward Research /ID# 282125 | Miramar | Florida | 33027 | Recruiting |
| Charter Research - Winter Park /ID# 281968 | Orlando | Florida | 32803-1839 | Recruiting |
| Florida Institute For Clinical Research /ID# 282739 | Orlando | Florida | 32825 | Recruiting |
| Progressive Medical Research /ID# 282838 | Port Orange | Florida | 32127 | Recruiting |
| Charter Research - The Villages /ID# 282376 | The Villages | Florida | 32162 | Recruiting |
| Metabolic Research Institute /ID# 282350 | West Palm Beach | Florida | 33401 | Recruiting |
| Encore Medical Research - Weston /ID# 282044 | Weston | Florida | 33331 | Recruiting |
| Elite Clinical Trials - Blackfoot /ID# 282042 | Blackfoot | Idaho | 83221 | Recruiting |
| L-MARC Research Center /ID# 282008 | Louisville | Kentucky | 40213 | Recruiting |
| Studymetrix Research /ID# 282163 | City of Saint Peters | Missouri | 63303 | Recruiting |
| Medication Management /ID# 281965 | Greensboro | North Carolina | 27405 | Recruiting |
| Monroe Biomedical Research /ID# 282009 | Monroe | North Carolina | 28112 | Recruiting |
| Centricity Research - Morehead city /ID# 283264 | Morehead City | North Carolina | 28557 | Recruiting |
| Lucas Research - New Bern /ID# 282747 | New Bern | North Carolina | 28562 | Recruiting |
| Accellacare - Tradd Court - Wilmington /ID# 282200 | Wilmington | North Carolina | 28401 | Recruiting |
| Lillestol Research LLC /ID# 281978 | Fargo | North Dakota | 58104 | Recruiting |
| CTI Clinical Research Center /ID# 282043 | Cincinnati | Ohio | 45212-3784 | Recruiting |
| Holston Medical Group - Bristol /ID# 282045 | Bristol | Tennessee | 37620 | Recruiting |
| New Phase Research & Development /ID# 282131 | Knoxville | Tennessee | 37909 | Recruiting |
| Summit Medical Group- Halls Family Physicians /ID# 282435 | Knoxville | Tennessee | 37938 | Recruiting |
| Clinical Research Associates - Nashville /ID# 282161 | Nashville | Tennessee | 37203 | Recruiting |
| Velocity Clinical Research - Dallas /ID# 282734 | Dallas | Texas | 75230 | Recruiting |
| Dcol Center For Clinical Research /ID# 281961 | Longview | Texas | 75605 | Recruiting |
| Washington Center For Weight Management And Research /ID# 282047 | Arlington | Virginia | 22206 | Recruiting |
| Sovah Health - Danville /ID# 282876 | Danville | Virginia | 24541 | Recruiting |
| Health Research Of Hampton Roads /ID# 282014 | Newport News | Virginia | 23606 | Recruiting |
| National Clinical Research /ID# 282007 | Richmond | Virginia | 23294 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Obesity trials
Other public records listing Obesity. Sorted by last update posted; newest first. Not a recommendation.
- NCT07792226: ENLIGHT Trial: ESG With Fundal Mucosal Ablation Not yet recruiting
- NCT07783802: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Not yet recruiting
- NCT07684144: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Recruiting
- NCT07554638: Incretin Therapies in Obesity-related HFpEF Recruiting
- NCT05921487: Time Restricted Eating to Mitigate Obesity in Veterans With Spinal Cord Injury Active, not recruiting
- NCT07770841: Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07752979, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07752979 live on ClinicalTrials.gov.